Curium Commits €32 Million to Saclay Site for European 177Lu-PSMA-I&T Production Line

Curium's €32 million capital commitment at its Saclay facility signals a concrete shift in European radiopharmaceutical manufacturing capacity, with direct implications for GMP readiness, site qualification, and supply continuity across the continent's growing radioligand therapy market. The investment, announced at the Choose France summit on 1 June 2026, will establish a dedicated production line for ¹⁷⁷Lu-PSMA-I&T, a targeted radioligand therapy (RLT) indicated for metastatic castration-resistant prostate cancer (mCRPC).

Saclay's selection reflects a deliberate site-strategy calculation. Curium's SVP Quality and Operations, Isabelle Rouzou, cited the quality of France's scientific, industrial, and hospital ecosystem, alongside its historic nuclear medicine expertise, as primary drivers. For plant heads evaluating analogous expansion decisions, the Saclay model illustrates how proximity to a legacy research infrastructure, here, the French Atomic Energy Commission (CEA), can reduce the qualification burden on a new GMP production line by anchoring it within an established technical environment.

The operational footprint being built around this investment is substantial. Curium already operates 13 production sites in France, serving more than 200 nuclear medicine centres daily, and employs over 750 people in-country. The Saclay expansion adds 20 highly skilled positions and extends that network's therapeutic reach beyond diagnostics into RLT supply. France currently accounts for more than 20% of Curium's global revenue, underscoring the strategic weight this site carries within the company's manufacturing network.

The broader investment context reinforces the scale of commitment: Curium has deployed more than €50 million across French operations over the past five years. The Saclay line is the most visible element of a programme designed to position the company ahead of a projected tenfold increase in RLT-eligible patients in France by 2035, a demand curve that will stress supply chains, batch release timelines, and qualified-person capacity across the sector if manufacturers do not begin scaling now.

For QA directors and regulatory leads, the theranostic positioning Curium is pursuing, integrating diagnostic and therapeutic radiopharmaceutical capabilities within a single site network, introduces compounded compliance considerations. 21 CFR Part 211 equivalents under EU GMP Annex 1 and the specific containment and release requirements for lutetium-177 conjugates will require validated processes and robust change-control frameworks as the new line moves from engineering to commercial-scale production.

The Saclay line's transition from construction to validated commercial output will serve as a measurable indicator of whether Europe's radiopharmaceutical manufacturing base can keep pace with the clinical adoption rate for targeted RLT in oncology.

Source: Curium via GlobeNewswire, 1 June 2026.